{"prompt": "['Trial ID: LP0162-1339', 'Date: 29-Aug-2018', 'Version: 4.0', 'Page 40 of 129', '9. A Worst Daily Pruritus numeric rating scale (NRS) average score of >4 during the', 'week prior to baseline.', 'Worst Daily Pruritus NRS at baseline will be calculated from daily assessments', 'of worst itch severity (Worst Daily Pruritus NRS) during the 7 days', 'immediately preceding randomisation (Day -6 to 0). A minimum of 4 Worst', 'Daily Pruritus NRS scores out of the 7 days is required to calculate the', 'baseline average score. For subjects who do not have at least 4 scores reported', 'during the 7 days immediately preceding the planned randomisation date,', 'randomisation should be postponed until this requirement is met, but without', \"exceeding the 6 weeks' maximum duration for screening.\", '10. Subjects must have applied a stable dose of emollient twice daily (or more, as needed)', 'for at least 14 days before randomisation.', '11. Women of child-bearing potential must use a highly effective* form of birth control', '(confirmed by the investigator) throughout the trial and at least for 16 weeks', '(5 half-lives) after last administration of IMP.', '*A highly effective method of birth control is defined as one which results in a low', 'failure rate (less than 1% per year) such as bilateral tubal occlusion, intrauterine', 'device (IUD), intrauterine hormone-releasing system (IUS), combined (oestrogen and', 'progestogen containing) hormonal contraception associated with inhibition of', 'ovulation (oral, intravaginal, transdermal), progestogen-only hormonal contraception', 'associated with inhibition of ovulation (oral, injectable, implantable), sexual', 'abstinence (when this is in line with the preferred and usual life style of the subject),', 'vasectomised partner (given that the subject is monogamous). The subjects must have', 'used the contraceptive method continuously for at least 1 month prior to the pregnancy', 'test at baseline. A female is defined as not being of child-bearing potential if she is', 'postmenopausal (at least 12 months with no menses without an alternative medical', 'cause prior to screening), or surgically sterile (hysterectomy, bilateral salpingectomy', 'or bilateral oophorectomy).', '8.3 Exclusion criteria', '1. Subjects for whom TCSs are medically inadvisable e.g., due to important side effects', 'or safety risks (including intolerance to treatment, hypersensitivity reactions,', 'significant skin atrophy, systemic effects etc.) in the opinion of the investigator.', 'TMF-000005673 - Version 4.0']['Trial ID: LP0162-1339', 'Date: 29-Aug-2018', 'Version: 4.0', 'Page 41 of 129', '2. Concurrent enrolment in another clinical trial where the subject is receiving an IMP.', '3. Previous randomisation in a tralokinumab clinical trial.', '4. Active dermatologic conditions that may confound the diagnosis of AD or would', 'interfere with assessment of treatment, such as scabies, cutaneous lymphoma, or', 'psoriasis.', '5. Known active allergic or irritant contact dermatitis that is likely to interfere with the', 'assessment of severity of AD.', '6. Use of tanning beds or phototherapy (narrow band ultraviolet B [NBUVB],', 'ultraviolet B [UVB], ultraviolet Al [UVA1], psoralen + ultraviolet A [PUVA]), within', '6 weeks prior to randomisation.', '7.', 'Treatment with the following medications within 4 weeks prior to randomisation:', 'Systemic immunosuppressive/immunomodulating drugs (e.g. methotrexate,', 'cyclosporine, azathioprine, mycophenolate-mofetil, Janus kinase inhibitors).', 'Systemic corticosteroid use (excludes topical, inhaled, or intranasal delivery).', 'Three or more bleach baths during any week within the 4 weeks.', '8. Treatment with the following medications within 2 weeks prior to randomisation', 'TCS.', 'TCI.', 'Topical phosphodiesterase 4 (PDE-4) inhibitor.', '9. Receipt of live attenuated vaccines 30 days prior to the date of randomisation and', 'during the trial including the safety follow-up period.', 'Receipt of inactive/killed vaccinations (e.g. inactive influenza) is allowed,', 'provided they are not administered within 5 days before/after any trial visit.', '10. Receipt of any marketed biological therapy (i.e. immunoglobulin, anti-IgE) including', 'dupilumab or investigational biologic agents:', 'Any cell-depleting agents including but not limited to rituximab: within', '6 months prior to randomisation, or until lymphocyte count returns to normal,', 'whichever is longer.', 'Other biologics: within 3 months or 5 half-lives, whichever is longer, prior to', 'randomisation.', 'TMF-000005673 - Version 4.0']\n\n###\n\n", "completion": "END"}